A daily pill reduces Parkinson's 'off-time' in a late-stage trial
The Times and the Independent reported a Parkinson's breakthrough in the form of a daily pill. Bloomberg reports that the maker, Cerevance, says its drug solengepras met its goals in a late-stage trial, reducing average off-time by about 37 minutes compared with placebo after 12 weeks, as an add-on to existing treatment. It works on a receptor called GPR6, not directly on dopamine. The claim of fewer side effects has not been compared head to head with other drugs.
Off-time, when medication wears off and symptoms return, is a large part of life with Parkinson's. A new mechanism offers an option when current drugs lose effect.
The drug is not approved. Patients should not change treatment.
Thirty-seven minutes is a modest average gain; the regulator's view of safety will decide how much it matters.
DailyDrop U.K. edition No. 3 · Morning · WED., OCT. 7, 2026